Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Trial to Evaluate the Efficacy of Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal Cancer Who Have Received FOLFOX + Panitumumab in First-line

Trial Profile

Phase II Clinical Trial to Evaluate the Efficacy of Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal Cancer Who Have Received FOLFOX + Panitumumab in First-line

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BEYOND TRIAL
  • Most Recent Events

    • 21 Nov 2018 Planned End Date changed from 4 Sep 2021 to 1 Dec 2021.
    • 11 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top